Revolution Medicines Inc

Revolution Medicines is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers, which represent a large and historically difficult-to-treat segment of solid tumors. The company's pipeline centers on RAS(ON) inhibitors — a class of drugs designed to suppress diverse oncogenic variants of RAS proteins. Its most advanced candidate, daraxonrasib (RMC-6236), is a RAS(ON) multi-selective inhibitor with an NDA under FDA review for previously treated metastatic pancreatic cancer, and is being studied across multiple tumor types and lines of therapy. The pipeline also includes elironrasib (RAS G12C-selective), zoldonrasib (RAS G12D-selective), and RMC-5127 (RAS G12V-selective), all in clinical development across pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Revolution Medicines has no approved products and generates no product revenue; it is funded through equity offerings, convertible notes, and a royalty funding arrangement with Royalty Pharma. The company has established an Expanded Access Program distributing daraxonrasib to over 2,000 patients and is building U.S. and global commercial infrastructure in preparation for a potential launch. Updated Aug 5, 2026